BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

19 results

Results per page: 10 20 30

New version of Iris version 6 is available for testing with ICD-11 Date: 16. December 2024 Topics: Kodiersysteme Type: News

The second test version of Iris version 6 for ICD-11 mortality coding has been released. You will find version 6.0.26 and the Iris Manual under “Downloads” on our website.

Save the date – next Iris webinar Date: 26. November 2024 Topics: Kodiersysteme Type: News

The next Iris webinar will be held on 11th December 2024.

Information letter on Airbufo Forspiro 160 µg/4,5 mg and 320 µg/9 mg: Possible failure of dose delivery from the first use PDF, 151KB, File does not meet accessibility standards Date: 22. November 2024 Topics: Pharmakovigilanz Type: Risk information

Active substance: budesonide and formoterole

The company Sandoz GmbH informs about a possible failure of dose delivery in several batches of Airbufo Forspiro.

Update of decision tables for Iris version 5 available Date: 28. October 2024 Topics: Kodiersysteme Type: News

We published updates of the decision tables (specV2021SR50Muse). The new decision tables are available in the Iris download area.

Save the date – next Iris webinar Date: 10. October 2024 Topics: Kodiersysteme Type: News

The next Iris webinar will be held on 13th November 2024.

Update of Iris version 5 Date: 09. September 2024 Topics: Kodiersysteme Type: News

We published a new version of the Iris software – V5.8.4-Y2024S2.

Information letter on Vitamin B12-ratiopharm N solution for injection: Recall due to visible particles PDF, 242KB, File does not meet accessibility standards Date: 03. September 2024 Topics: Pharmakovigilanz Type: Risk information

Active substance: vitamine B12

The company ratiopharm GmbH informs about a precautionary recall of all batches on the market due to visible particles

Mysimba (naltrexone/bupropion): EMA advises about risks of using weight loss medicine Mysimba with opioids Date: 29. July 2024 Topics: Pharmakovigilanz Type: Risk information

Active substance: naltrexon, bupropion

The European Medicines Agency (EMA) draws attention to the risks of using the weight loss medication Mysimba in combination with opioids.

Start of a review concerning the conduct of studies at Synapse Labs Pvt. Ltd., India Date: 15. July 2024 Topics: Pharmakovigilanz Type: Risk information

Active substance: various

The Federal Institute for Drugs and Medical Devices (BfArM) implements the decision of the European Commission of 24 May 2024 for the German marketing authorisations with its decision of 17 June 2024.

Medicinal products containing hydroxyprogesterone: Safety review Date: 02. July 2024 Topics: Pharmakovigilanz Type: Risk information

Active substance: hydroxyprogesterone

Hydroxyprogesterone caproate medicines to be suspended from the EU market.